{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:16:27Z","timestamp":1783617387452,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40121-026-01383-8","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:16:14Z","timestamp":1781316974000},"page":"2145-2165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Data on the Use of Intravenous Fosfomycin for the Treatment of Central Nervous System Infections: a Subgroup Analysis from the FORTRESS Study"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct02979951","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0480-2089","authenticated-orcid":false,"given":"Dominik","family":"Jarczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kieninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zoller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Spies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kintrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Antonitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Zundel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Del Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Galfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Iasonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campogiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit M.","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias G.","family":"Vossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio M.","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus-Friedrich","family":"Bodmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the FORTRESS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"1383_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/14787210.2025.2565581","volume":"23","author":"J Gorham","year":"2025","unstructured":"Gorham J, Yousfi H, Taccone FS, Salvagno M, Hites M. Optimal antibiotic therapy for bacterial central nervous system infections in adults. Expert Rev Anti Infect Ther. 2025;23:917\u201332. https:\/\/doi.org\/10.1080\/14787210.2025.2565581.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1383_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/14787210.2020.1754193","volume":"18","author":"KG Tsegka","year":"2020","unstructured":"Tsegka KG, Voulgaris GL, Kyriakidou M, Falagas ME. Intravenous fosfomycin for the treatment of patients with central nervous system infections: evaluation of the published evidence. Expert Rev Anti Infect Ther. 2020;18:657\u201368. https:\/\/doi.org\/10.1080\/14787210.2020.1754193.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1383_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/cmr.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29:321\u201347. https:\/\/doi.org\/10.1128\/cmr.00068-15.","journal-title":"Clin Microbiol Rev"},{"key":"1383_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/jac\/dkh158","volume":"53","author":"B Pfausler","year":"2004","unstructured":"Pfausler B, Spiss H, Dittrich P, Zeitlinger M, Schmutzhard E, Joukhadar C. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother. 2004;53:848\u201352. https:\/\/doi.org\/10.1093\/jac\/dkh158.","journal-title":"J Antimicrob Chemother"},{"key":"1383_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14121247","volume":"14","author":"E Wohlfarth","year":"2025","unstructured":"Wohlfarth E, Dinh A, Vrioni G, \u017babicka D, Bernardo M, Tascini C, et al. In vitro evaluation of fosfomycin combinations against metallo-\u03b2-lactamase-producing Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates. Antibiotics. 2025;14:1247. https:\/\/doi.org\/10.3390\/antibiotics14121247.","journal-title":"Antibiotics"},{"key":"1383_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40121-025-01125-2","volume":"14","author":"K-F Bodmann","year":"2025","unstructured":"Bodmann K-F, Hagel S, Oliva A, Kluge S, Mularoni A, Galfo V, et al. Real-world use, effectiveness, and safety of intravenous fosfomycin: the FORTRESS study. Infect Dis Ther. 2025;14:765\u201391. https:\/\/doi.org\/10.1007\/s40121-025-01125-2.","journal-title":"Infect Dis Ther"},{"key":"1383_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s15010-019-01323-4","volume":"47","author":"C Putensen","year":"2019","unstructured":"Putensen C, Ellger B, Sakka SG, Weyland A, Schmidt K, Zoller M, et al. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019;47:827\u201336. https:\/\/doi.org\/10.1007\/s15010-019-01323-4.","journal-title":"Infection"},{"key":"1383_CR8","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/jac\/dkae253","volume":"79","author":"DA Butler","year":"2024","unstructured":"Butler DA, Patel N, O\u2019Donnell JN, Lodise TP. Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature. J Antimicrob Chemother. 2024;79:2421\u201359. https:\/\/doi.org\/10.1093\/jac\/dkae253.","journal-title":"J Antimicrob Chemother"},{"key":"1383_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/antibiotics12060971","volume":"12","author":"A Anastasia","year":"2023","unstructured":"Anastasia A, Bonura S, Rubino R, Giammanco GM, Miccich\u00e8 I, Di Pace MR, et al. The use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in Italy. Antibiotics (Basel). 2023;12:971. https:\/\/doi.org\/10.3390\/antibiotics12060971.","journal-title":"Antibiotics (Basel)"},{"key":"1383_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/14787210.2021.1932463","volume":"20","author":"KG Tsegka","year":"2022","unstructured":"Tsegka KG, Voulgaris GL, Kyriakidou M, Kapaskelis A, Falagas ME. Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review. Expert Rev Anti Infect Ther. 2022;20:33\u201343. https:\/\/doi.org\/10.1080\/14787210.2021.1932463.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"1383_CR11","first-page":"19","volume":"32","author":"A Rodr\u00edguez-Gasc\u00f3n","year":"2019","unstructured":"Rodr\u00edguez-Gasc\u00f3n A, Canut-Blasco A. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin. Rev Esp Quimioter. 2019;32(Suppl 1):19\u201324.","journal-title":"Rev Esp Quimioter"},{"key":"1383_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12941-023-00572-4","volume":"22","author":"C K\u00f6nig","year":"2023","unstructured":"K\u00f6nig C, Martens-Lobenhoffer J, Czorlich P, Westphal M, Bode-B\u00f6ger SM, Kluge S, et al. Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: an observational study. Ann Clin Microbiol Antimicrob. 2023;22:29. https:\/\/doi.org\/10.1186\/s12941-023-00572-4.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"1383_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1046\/j.1365-2125.2002.01659.x","volume":"54","author":"M Brunner","year":"2002","unstructured":"Brunner M, Reinprecht A, Illievich U, Spiss CK, Dittrich P, van Houte M, et al. Penetration of fosfomycin into the parenchyma of human brain: a case study in three patients. Br J Clin Pharmacol. 2002;54:548\u201350. https:\/\/doi.org\/10.1046\/j.1365-2125.2002.01659.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1383_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/BF01647220","volume":"15","author":"E K\u00fchnen","year":"1987","unstructured":"K\u00fchnen E, Pfeifer G, Frenkel C. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection. 1987;15:422\u20134. https:\/\/doi.org\/10.1007\/BF01647220.","journal-title":"Infection"},{"key":"1383_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","volume":"47","author":"KZ Vardakas","year":"2016","unstructured":"Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47:269\u201385. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.001.","journal-title":"Int J Antimicrob Agents"},{"key":"1383_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3325\/cmj.2018.59.56","volume":"59","author":"L Bielen","year":"2018","unstructured":"Bielen L, Liki\u0107 R, Erdelji\u0107 V, Marekovi\u0107 I, Firis N, Grgi\u0107-Medi\u0107 M, et al. Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study. Croat Med J. 2018;59:56\u201364. https:\/\/doi.org\/10.3325\/cmj.2018.59.56.","journal-title":"Croat Med J"},{"key":"1383_CR17","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.2147\/IDR.S385411","volume":"15","author":"R Shrief","year":"2022","unstructured":"Shrief R, El-Ashry AH, Mahmoud R, El-Mahdy R. Effect of colistin, fosfomycin and meropenem\/vaborbactam on carbapenem-resistant Enterobacterales in Egypt: a cross-sectional study. Infect Drug Resist. 2022;15:6203\u201314. https:\/\/doi.org\/10.2147\/IDR.S385411.","journal-title":"Infect Drug Resist"},{"key":"1383_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11121441","volume":"11","author":"B Kowalska-Krochmal","year":"2022","unstructured":"Kowalska-Krochmal B, M\u0105czy\u0144ska B, Rura\u0144ska-Smutnicka D, Secewicz A, Krochmal G, Bartelak M, et al. Assessment of the susceptibility of clinical gram-negative and gram-positive bacterial strains to fosfomycin and significance of this antibiotic in infection treatment. Pathogens Basel. 2022;11:1441. https:\/\/doi.org\/10.3390\/pathogens11121441.","journal-title":"Pathogens Basel"},{"key":"1383_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms13050963","volume":"13","author":"S Tedeschi","year":"2025","unstructured":"Tedeschi S, Giannitsioti E, Mayer C. Emerging concepts for the treatment of biofilm-associated bone and joint infections with IV fosfomycin: a literature review. Microorganisms. 2025;13:963. https:\/\/doi.org\/10.3390\/microorganisms13050963.","journal-title":"Microorganisms"},{"key":"1383_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9080500","volume":"9","author":"RM Antonello","year":"2020","unstructured":"Antonello RM, Principe L, Maraolo AE, Viaggi V, Pol R, Fabbiani M, et al. Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies. Antibiotics. 2020;9:500. https:\/\/doi.org\/10.3390\/antibiotics9080500.","journal-title":"Antibiotics"},{"key":"1383_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-025-00841-3","volume":"214","author":"A Nussbaumer-Pr\u00f6ll","year":"2025","unstructured":"Nussbaumer-Pr\u00f6ll A, Oberm\u00fcller M, Weiss-Tessbach M, Eberl S, Zeitlinger M, Matiba B, et al. Synergistic activity of fosfomycin and flucloxacillin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus: in vitro and in vivo assessment. Med Microbiol Immunol. 2025;214:32. https:\/\/doi.org\/10.1007\/s00430-025-00841-3.","journal-title":"Med Microbiol Immunol"},{"key":"1383_CR22","first-page":"264","volume":"46","author":"MT Della Rocca","year":"2023","unstructured":"Della Rocca MT, Di Caprio G, Colucci F, Merola F, Panetta V, Cordua E, et al. Fosfomycin-meropenem synergistic combination against NDM carbapenemase-producing Klebsiella pneumoniae strains. New Microbiol. 2023;46:264\u201370.","journal-title":"New Microbiol"},{"key":"1383_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121653","volume":"12","author":"G Pipitone","year":"2023","unstructured":"Pipitone G, Di Bella S, Maraolo AE, Granata G, Gatti M, Principe L, et al. Intravenous fosfomycin for systemic multidrug-resistant Pseudomonas aeruginosa infections. Antibiotics Basel. 2023;12:1653. https:\/\/doi.org\/10.3390\/antibiotics12121653.","journal-title":"Antibiotics Basel"},{"key":"1383_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00126-19","volume":"63","author":"J Albiero","year":"2019","unstructured":"Albiero J, Mazucheli J, Barros JPDR, Szczerepa MMDA, Nishiyama SAB, Carrara-Marroni FE, et al. Pharmacodynamic attainment of the synergism of Meropenem and Fosfomycin combination against Pseudomonas aeruginosa producing metallo-\u03b2-lactamase. Antimicrob Agents Chemother. 2019;63:e00126-19. https:\/\/doi.org\/10.1128\/AAC.00126-19.","journal-title":"Antimicrob Agents Chemother"},{"key":"1383_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/1120009X.2020.1745501","volume":"32","author":"B Erturk Sengel","year":"2020","unstructured":"Erturk Sengel B, Altinkanat Gelmez G, Soyletir G, Korten V. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and\/or NDM-producing Klebsiella pneumoniae. J Chemother. 2020;32:237\u201343. https:\/\/doi.org\/10.1080\/1120009X.2020.1745501.","journal-title":"J Chemother"},{"key":"1383_CR26","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1089\/mdr.2018.0234","volume":"25","author":"D Ojdana","year":"2019","unstructured":"Ojdana D, Gutowska A, Sacha P, Majewski P, Wieczorek P, Tryniszewska E. Activity of ceftazidime-avibactam alone and in combination with ertapenem, fosfomycin, and tigecycline against carbapenemase-producing Klebsiella pneumoniae. Microb Drug Resist. 2019;25:1357\u201364. https:\/\/doi.org\/10.1089\/mdr.2018.0234.","journal-title":"Microb Drug Resist"},{"key":"1383_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.diagmicrobio.2019.05.014","volume":"95","author":"LM Avery","year":"2019","unstructured":"Avery LM, Sutherland CA, Nicolau DP. In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2019;95:216\u201320. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.014.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1383_CR28","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/jac\/dkr296","volume":"66","author":"B Ber\u00e7ot","year":"2011","unstructured":"Ber\u00e7ot B, Poirel L, Dortet L, Nordmann P. In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae. J Antimicrob Chemother. 2011;66:2295\u20137. https:\/\/doi.org\/10.1093\/jac\/dkr296.","journal-title":"J Antimicrob Chemother"},{"key":"1383_CR29","unstructured":"Foundation for Statistical Computing (Vienna, Austria). R: a language and environment for statistical computing\u2014the R Project for Statistical Computing [Internet]. [cited 2025 Jan 26]. https:\/\/www.r-project.org\/. Accessed 26 Jan 2025."},{"key":"1383_CR30","unstructured":"Heinze G, Ploner M, Jiricka L, Steiner G. logistf: Firth\u2019s bias-reduced logistic regression. R package version 1.26.1 [Internet]. 2025 [cited 2026 Jan 22]. https:\/\/github.com\/georgheinze\/logistf. Accessed 22 Jan 2026."},{"key":"1383_CR31","first-page":"422","volume":"103","author":"B Shahan","year":"2021","unstructured":"Shahan B, Choi EY, Nieves G. Cerebrospinal fluid analysis. Aust Fam Physician. 2021;103:422\u20138.","journal-title":"Aust Fam Physician"},{"key":"1383_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw077","volume":"3","author":"C Srihawan","year":"2016","unstructured":"Srihawan C, Castelblanco RL, Salazar L, Wootton SH, Aguilera E, Ostrosky-Zeichner L, et al. Clinical characteristics and predictors of adverse outcome in adult and pediatric patients with healthcare-associated ventriculitis and meningitis. Open Forum Infect Dis. 2016;3:ofw077. https:\/\/doi.org\/10.1093\/ofid\/ofw077.","journal-title":"Open Forum Infect Dis"},{"key":"1383_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf655","volume":"12","author":"VB Allen","year":"2025","unstructured":"Allen VB, Raslan A, Muuli AM, Alkhafaji NY, Bechman K, Wijeweera KDDS, et al. Epidemiology of brain abscess: a retrospective cohort from a neurosurgical tertiary referral center in England. Open Forum Infect Dis. 2025;12:ofaf655. https:\/\/doi.org\/10.1093\/ofid\/ofaf655.","journal-title":"Open Forum Infect Dis"},{"key":"1383_CR34","unstructured":"Epidemiology Network (EPI-Net). EPI-Net annual report of EU epidemiological scenarios 2025 [Internet]. 2025 [cited 2026 Feb 21]. https:\/\/epi-net.eu\/reports\/. Accessed 21 Feb 2026."},{"key":"1383_CR35","unstructured":"Bayerisches Landesamt f\u00fcr Gesundheit und Lebensmittelsicherheit. Bayerische Antibiotikaresistenz\u2011Datenbank (BARDa)\u2014Antibiotikareistenzen erstes Halbjahr 2022 [Internet]. 2023 [cited 2026 Feb 21]. https:\/\/www.lgl.bayern.de\/gesundheit\/infektionsschutz\/barda\/2022_1_staphylococcus_epidermidis.htm. Accessed 21 Feb 2026."},{"key":"1383_CR36","unstructured":"Robert Koch Institut (RKI). AMR\u2014Surveillance [Internet]. [cited 2026 Feb 21]. https:\/\/amr.rki.de\/Content\/Datenbank\/ARS\/ResistanceOverview.aspx. Accessed 21 Feb 2026."},{"key":"1383_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10010154","volume":"10","author":"M Gatti","year":"2022","unstructured":"Gatti M, Virgili G, Cojutti PG, Gaibani P, Conti M, Sturiale C, et al. Real-time optimization of pharmacodynamic target attainment at infection site during treatment of post-neurosurgical ventriculitis caused by carbapenem-resistant Gram negatives with ceftazidime\u2013avibactam-based regimens: a report of two cases. Microorganisms (Basel). 2022;10:154. https:\/\/doi.org\/10.3390\/microorganisms10010154.","journal-title":"Microorganisms (Basel)"},{"key":"1383_CR38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jgar.2024.03.003","volume":"37","author":"L Volpicelli","year":"2024","unstructured":"Volpicelli L, Cairoli S, Al Ismail D, Baisi F, Sacco F, Goffredo BM, et al. Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem\/vaborbactam and high dose of fosfomycin. J Glob Antimicrob Resist. 2024;37:86\u201390. https:\/\/doi.org\/10.1016\/j.jgar.2024.03.003.","journal-title":"J Glob Antimicrob Resist"},{"key":"1383_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/BF02619876","volume":"31","author":"M Trummer","year":"1999","unstructured":"Trummer M, Eustacchio S, Unger F. Prognose und Therapie posttraumatischer intrakranieller Abszesse und Empyeme. Acta Chir Austriaca. 1999;31:32\u20135. https:\/\/doi.org\/10.1007\/BF02619876.","journal-title":"Acta Chir Austriaca"},{"key":"1383_CR40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/00365548.2011.616221","volume":"44","author":"A Dinh","year":"2012","unstructured":"Dinh A, Salomon J, Bru JP, Bernard L. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis. 2012;44:182\u20139. https:\/\/doi.org\/10.3109\/00365548.2011.616221.","journal-title":"Scand J Infect Dis"},{"key":"1383_CR41","doi-asserted-by":"publisher","DOI":"10.1590\/S1678-9946202365023","volume":"65","author":"T Tunckale","year":"2023","unstructured":"Tunckale T, Kavak C, Safak B, Gonen A, Erdem I. A case report of brain abscess caused by carbapenem-resistant Klebsiella pneumoniae. Rev Inst Med Trop Sao Paulo. 2023;65:e23. https:\/\/doi.org\/10.1590\/S1678-9946202365023.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"1383_CR42","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jmii.2011.09.012","volume":"45","author":"W-S Lee","year":"2012","unstructured":"Lee W-S, Wang F-D, Shieh Y-H, Teng S-O, Ou T-Y. Lemierre syndrome complicating multiple brain abscesses caused by extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae cured by fosfomycin and meropenem combination therapy. J Microbiol Immunol Infect. 2012;45:72\u20134. https:\/\/doi.org\/10.1016\/j.jmii.2011.09.012.","journal-title":"J Microbiol Immunol Infect"},{"key":"1383_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/978-3-7091-8903-0_6","volume-title":"New aspects for treatment with fosfomycin [Internet]","author":"H Tritthart","year":"1987","unstructured":"Tritthart H. Fosfomycin in cerebral and spinal abscesses. In: Guggenbichler J-P, editor. New aspects for treatment with fosfomycin [Internet]. Vienna: Springer; 1987. p. 58\u201366. https:\/\/doi.org\/10.1007\/978-3-7091-8903-0_6. (cited 2026 Feb 21)."},{"key":"1383_CR44","first-page":"98","volume":"15","author":"H Friedrich","year":"1987","unstructured":"Friedrich H, Engel E, Potel J. Fosfomycin levels in the cerebrospinal fluid of patients with and without meningitis. Immun Infekt. 1987;15:98\u2013102.","journal-title":"Immun Infekt"},{"key":"1383_CR45","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1128\/AAC.49.11.4448-4454.2005","volume":"49","author":"R Sauermann","year":"2005","unstructured":"Sauermann R, Karch R, Langenberger H, Kettenbach J, Mayer-Helm B, Petsch M, et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother. 2005;49:4448\u201354. https:\/\/doi.org\/10.1128\/AAC.49.11.4448-4454.2005.","journal-title":"Antimicrob Agents Chemother"},{"key":"1383_CR46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/1120009X.2022.2149186","volume":"35","author":"P Aysert-Yildiz","year":"2023","unstructured":"Aysert-Yildiz P, \u00d6zgen-Top \u00d6, Habibi H, Dizbay M. Efficacy and safety of intravenous fosfomycin for the treatment of carbapenem-resistant Klebsiella pneumoniae. J Chemother. 2023;35:471\u20136. https:\/\/doi.org\/10.1080\/1120009X.2022.2149186.","journal-title":"J Chemother"},{"key":"1383_CR47","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jgar.2023.03.010","volume":"33","author":"G Zhanel","year":"2023","unstructured":"Zhanel G, Baxter M, Wong M, Mirzanejad Y, Lee A, Dhami R, et al. Real-life experience with IV fosfomycin in Canada: results from the Canadian leadership on antimicrobial real-life usage (CLEAR) registry. J Glob Antimicrob Resist. 2023;33:171\u20136. https:\/\/doi.org\/10.1016\/j.jgar.2023.03.010.","journal-title":"J Glob Antimicrob Resist"},{"key":"1383_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09541-4","volume":"24","author":"S Biscarini","year":"2024","unstructured":"Biscarini S, Mangioni D, Bobbio C, Mela L, Alagna L, Baldelli S, et al. Adverse events during intravenous fosfomycin therapy in a real-life scenario. Risk factors and the potential role of therapeutic drug monitoring. BMC Infect Dis. 2024;24:650. https:\/\/doi.org\/10.1186\/s12879-024-09541-4.","journal-title":"BMC Infect Dis"},{"key":"1383_CR49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijantimicag.2010.09.002","volume":"37","author":"A Florent","year":"2011","unstructured":"Florent A, Chichmanian R-M, Cua E, Pulcini C. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37:82\u20133. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.09.002.","journal-title":"Int J Antimicrob Agents"},{"key":"1383_CR50","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1038\/s41591-023-02569-0","volume":"29","author":"S Grillo","year":"2023","unstructured":"Grillo S, Pujol M, Mir\u00f3 JM, L\u00f3pez-Contreras J, Euba G, Gasch O, et al. Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial. Nat Med. 2023;29:2518\u201325. https:\/\/doi.org\/10.1038\/s41591-023-02569-0.","journal-title":"Nat Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01383-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01383-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01383-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:06:15Z","timestamp":1783616775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01383-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01383-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The following authors declare potential conflicts of interest unrelated to the submitted work: Stefan Kluge received research support from Biotest, CytoSorbents, Daiichi Sankyo and Fresenius Medical Care. He also received lecture fees from ADVITOS, bioM\u00e9rieux GmbH, CSL Behring, Gilead, MSD, Pfizer and Shionogi. He received consultant fees from ADVITOS, Gilead and Pfizer. Stefan Hagel has received honoraria from Pfizer, MSD, InfectoPharm, Philips, Advanz Pharma, Beckman Coulter, Shionogi, Thermo Fisher and Tillots. He also participated in advisory boards for Advanz Pharma, Shionogi and Pfizer. Mathias W. Pletz received grants from Pfizer, consulting fees from Sanofi and Pfizer and honoraria for lectures and presentations from Pfizer, MSD, Sanofi, Janssen, GSK, AstraZeneca, Shionogi, InfectoPharm, bioM\u00e9rieux and Moderna. He also reports support for attending meetings from Pfizer, MSD, Sanofi, bioM\u00e9rieux and Shionogi and having participated in advisory boards from bioM\u00e9rieux, Sanofi, Pfizer, GSK, AstraZeneca, Shionogi, InfectoPharm, Tillotts and Moderna. Claudia Spies participated in advisory boards for Takeda Pharmaceutical, Lynx Health Science GmbH, Mundipharma, PAION Pharma GmbH. Loredana Sarmati received travel grants from Gilead, Merck, Pfizer and Advanz. She also received honoraria for lectures from Merck, Gilead, Abbvie, Angelini, AstraZeneca and GSK. Laura Campogiani received a research grant from Gilead and honoraria for lectures from Menarini, MICOM and Nadirex. She also reports support for attending meetings from Menarini, Shionogi and Pfizer. Matthias G. Vossen received consulting fees and speaker honoraria from Astro Pharma. Klaus-Friedrich Bodmann has received honoraria for lectures from Abbott, Accelerate, Correvio, InfectoPharm, Pfizer, Weber & Weber and Shionogi. Carina Herbst and Christian Mayer are employees of InfectoPharm, Heppenheim, Germany. Dominik Jarczak, Martin Kieninger, Michael Zoller, Sebastian Kintrup, Lukas Antonitsch, J\u00f6rg Zundel, Valerio Del Bono, Valentina Galfo, Marco Falcone, Christina Iasonidou, Abhijit M. Bal, George Dimopoulos and Claudio M. Mastroianni have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki of 1964 (and its amendments) and was approved by the ethics committees or other authorities of the respective participating centres, according to national and local requirements, as described previously [\n                      \n                      ]. Written informed consent was obtained from each patient or the patient\u2019s legally acceptable representative before any study-specific activity was performed. In Austria, an informed consent waiver was approved for patients who were incapacitated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}